Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2009 1
2017 1
2018 2
2019 1
2020 1
2021 1
2022 1
2023 3
2024 5
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for r jazaeri
Your search for R Jazaei retrieved no results
Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial.
How JA, Dang M, Lee S, Fellman B, Westin SN, Sood AK, Fleming ND, Shafer A, Yuan Y, Liu J, Zhao L, Celestino J, Hajek R, Morgan MB, Parra ER, Laberiano Fernandez CD, Arrechedera CA, Solis Soto LM, Schmeler KM, Nick A, Lu KH, Coleman R, Wang L, Jazaeri AA. How JA, et al. Med. 2025 Jan 10;6(1):100494. doi: 10.1016/j.medj.2024.07.022. Epub 2024 Aug 15. Med. 2025. PMID: 39151421 Clinical Trial.
Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial.
Wermke M, Araujo DM, Chatterjee M, Tsimberidou AM, Holderried TAW, Jazaeri AA, Reshef R, Bokemeyer C, Alsdorf W, Wetzko K, Brossart P, Aslan K, Backert L, Bunk S, Fritsche J, Gulde S, Hengler S, Hilf N, Hossain MB, Hukelmann J, Kalra M, Krishna D, Kursunel MA, Maurer D, Mayer-Mokler A, Mendrzyk R, Mohamed A, Pozo K, Satelli A, Letizia M, Schuster H, Schoor O, Wagner C, Rammensee HG, Reinhardt C, Singh-Jasuja H, Walter S, Weinschenk T, Luke JJ, Britten CM. Wermke M, et al. Nat Med. 2025 Jul;31(7):2365-2374. doi: 10.1038/s41591-025-03650-6. Epub 2025 Apr 9. Nat Med. 2025. PMID: 40205198 Free PMC article. Clinical Trial.
Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities.
Knisely A, Dai Y, Barlow GL, Lee S, Lawson B, Clark H, Fellman B, Yuan Y, Lu W, Lubo Julio IC, Lazcano RN, Chelvanambi M, Melendez B, Singh B, Singh B, Wani K, Chen J, Yeh CC, Gao J, Barnes S, Shi O, Khan KB, Serrano AG, Gomez-Bolanos LI, Scalise CB, Cheung SK, Dutta P, Velichko S, ElNaggar AC, Liu MC, Wilke RN, How J, Ramondetta LM, Boruta DM, Richardson G, Shafer A, Westin SN, Sims T, Sood AK, Ramirez PT, Lazar AJ, Soliman PT, Lu K, Haymaker CL, Solis Soto LM, Wargo JA, Grisham R, Wucherpfennig KW, Wang L, Jazaeri AA. Knisely A, et al. Clin Cancer Res. 2025 Oct 1;31(19):4122-4135. doi: 10.1158/1078-0432.CCR-25-0512. Clin Cancer Res. 2025. PMID: 40748258 Free PMC article.
Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers.
Son J, Zhang Y, Lin H, Mirallas O, Alvarez Ballesteros P, Nardo M, Clark N, Hillman RT, Campbell E, Holla V, Johnson AM, Biter AB, Yuan Y, Cobb LP, Gershenson DM, Jazaeri AA, Lu KH, Soliman PT, Westin SN, Euscher ED, Lawson BC, Yang RK, Meric-Bernstam F, Hong DS. Son J, et al. Clin Cancer Res. 2024 Jul 15;30(14):2986-2995. doi: 10.1158/1078-0432.CCR-23-2819. Clin Cancer Res. 2024. PMID: 38687597 Free PMC article.
Transforming ovarian cancer care by targeting minimal residual disease.
Jazaeri AA, Grisham R, Knisely A, Spranger S, Zamarin D, Hillman RT, Lawson BC, Burns KH, Lee S, Westin SN, Moiso E, Williams MJ, Bardhan NM, Pisanic T, Matulonis U, Weigelt B, Shih I, Konstantinopoulos PA, Gaillard S, Wang L, Aghajanian C, D'Andrea AD, Hammond P, Shah S, Wucherpfennig KW, Lu KH. Jazaeri AA, et al. Med. 2023 Nov 10;4(11):755-760. doi: 10.1016/j.medj.2023.08.004. Med. 2023. PMID: 37951209 Free PMC article.
Potential immunotherapy targets in recurrent cervical cancer.
Ring KL, Yemelyanova AV, Soliman PT, Frumovitz MM, Jazaeri AA. Ring KL, et al. Gynecol Oncol. 2017 Jun;145(3):462-468. doi: 10.1016/j.ygyno.2017.02.027. Epub 2017 Feb 21. Gynecol Oncol. 2017. PMID: 28233576
Although there was a higher median density of intratumoral cytotoxic T cells and macrophages compared to regulatory T cells (median density CD8+ 83.5 vs 35.6, p<0.05, median density 196.7 vs 35.6, p<0.05), the presence of macrophages correlated with the presence of regulato …
Although there was a higher median density of intratumoral cytotoxic T cells and macrophages compared to regulatory T cells (median density …
Enhanced fluid drainage using a novel multi-pod drainage catheter: An in vitro evaluation.
Al-Jazaeri A, Alhammad A, Almuhaideb M, Alyahya A, Al-Jazaeri S, Alyami F. Al-Jazaeri A, et al. Technol Health Care. 2023;31(6):2155-2164. doi: 10.3233/THC-230015. Technol Health Care. 2023. PMID: 37302053
BACKGROUND: A multi-pod catheter (MPC) is a large drainage catheter that can house multiple smaller retractable (MPC-R) and deployable catheters (MPC-D) within the body. OBJECTIVE: The drainage capabilities and resistance to clogging of a novel MPC have been assessed. ...R …
BACKGROUND: A multi-pod catheter (MPC) is a large drainage catheter that can house multiple smaller retractable (MPC-R) and deployabl …
Reliability, validity, and diagnostic accuracy of the apathy evaluation scale in chronic stroke survivors.
Jamali A, Baluchnejadmojarad T, Jazaeri SZ, Abedi S, Mehdizadeh H, Sharabiani PTA, Taghizadeh G. Jamali A, et al. BMC Psychiatry. 2025 Mar 5;25(1):201. doi: 10.1186/s12888-025-06626-5. BMC Psychiatry. 2025. PMID: 40045280 Free PMC article.
Significant moderate to high correlation (r or w = -0.34-0.69) was found between three AES versions and HADS-D, HADS-A, BI, and mRS. ...
Significant moderate to high correlation (r or w = -0.34-0.69) was found between three AES versions and HADS-D, HADS-A, BI, and mRS. …
Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer.
Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. Lee S, et al. Cell Rep. 2020 Apr 14;31(2):107502. doi: 10.1016/j.celrep.2020.03.066. Cell Rep. 2020. PMID: 32294438 Free PMC article.
21 results